FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to treating diseases or conditions, in which proprotein convertase subtilisin/kexin type 9 (hPCSK9) expression or activity is involved. For this purpose it is performed administration of hPCSK9-specific antibodies or antigen-binding fragments thereof. At that, the pharmaceutical composition contains a fixed doses of the above antibody of 75, 150 or 300 mg. Administration of the composition is performed every two or four weeks.
EFFECT: said administration schedule of the composition provides the effective treatment of said diseases or pathological conditions with minimal side effects.
25 cl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES TO HUMAN PCSK9 | 2012 |
|
RU2604139C2 |
| HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING SPECIFIC GROUPS OF INDIVIDUALS | 2012 |
|
RU2721279C2 |
| HIGH-AFFINITY HUMAN ANTI-PCSK9 ANTIBODIES | 2009 |
|
RU2552169C2 |
| HIGH AFFINITY HUMAN PCSK9 ANTIBODIES | 2009 |
|
RU2697773C2 |
| METHODS FOR TREATMENT OF HYPERLIPIDEMIA IN PATIENTS WITH DIABETES BY INJECTION OF PCSK9 INHIBITOR | 2018 |
|
RU2772712C2 |
| METHODS OF TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) | 2015 |
|
RU2735521C2 |
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
| TREATING WITH ANTI-PCSK9 ANTIBODIES | 2012 |
|
RU2576034C2 |
| APPLICATION OF ROSUVASTATIN (ZD-4522) IN TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | 2001 |
|
RU2294744C2 |
| PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
